Idiosyncratic drug-induced liver injury (IDILI) is a rare but potentially severe adverse drug
reaction that should be considered in patients who develop laboratory criteria for liver injury …

Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …

Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-
T790M–mutated NSCLC, but osimertinib-resistant EGFR triple mutations …

The tyrosine kinase activity of epidermal growth factor receptors (EGFRs) plays critical roles
in cell proliferation, regeneration, tumorigenesis, and anticancer resistance. Non-small-cell …

Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …

Abstract The EGFR C797S mutation is the most common on-target resistance mechanism to
osimertinib in patients with advanced non–small cell lung cancer (NSCLC). Currently there …

Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

Background Osimertinib became the standard treatment for patients with untreated EGFR-
mutant advanced non-small cell lung cancer (aNSCLC) following results reported in the …

Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …